Two Sigma Advisers’s Gilead Sciences GILD Stock Holding History

Two Sigma Advisers’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52,000	Closed	-$6.38M	–	867
2025 Q4	$6.38M	Buy	52,000 +30,900	+146%	+$3.76M	0.01%	704
2025 Q3	$2.34M	Buy	21,100 +3,000	+17%	+$341K	﹤0.01%	1069
2025 Q2	$2.01M	Buy	18,100 +13,700	+311%	+$1.46M	﹤0.01%	1119
2025 Q1	$493K	Sell	4,400 -266,396	-98%	-$27.5M	﹤0.01%	1789
2024 Q4	$25M	Sell	270,796 -2,217,004	-89%	-$200M	0.06%	263
2024 Q3	$209M	Sell	2,487,800 -3,767,900	-60%	-$288M	0.49%	49
2024 Q2	$429M	Buy	6,255,700 +1,176,100	+23%	+$78.5M	0.96%	17
2024 Q1	$372M	Buy	5,079,600 +3,910,300	+334%	+$301M	0.86%	19
2023 Q4	$94.7M	Sell	1,169,300 -2,542,500	-68%	-$198M	0.22%	105
2023 Q3	$278M	Sell	3,711,800 -268,500	-7%	-$20.7M	0.71%	27
2023 Q2	$307M	Sell	3,980,300 -1,256,100	-24%	-$100M	0.78%	23
2023 Q1	$434M	Buy	5,236,400 +189,900	+4%	+$15.7M	1.12%	8
2022 Q4	$433M	Sell	5,046,500 -816,000	-14%	-$64.6M	1.21%	8
2022 Q3	$362M	Buy	5,862,500 +344,800	+6%	+$21.7M	1.05%	15
2022 Q2	$341M	Buy	5,517,700 +918,800	+20%	+$56.9M	0.97%	13
2022 Q1	$273M	Buy	4,598,900 +1,155,800	+34%	+$73.9M	0.73%	25
2021 Q4	$250M	Sell	3,443,100 -1,284,000	-27%	-$88.4M	0.63%	43
2021 Q3	$330M	Buy	4,727,100 +4,704,199	+20,541%	+$330M	0.86%	25
2021 Q2	$1.58M	Buy	+22,901	New	+$1.53M	﹤0.01%	1421
2020 Q4	–	Sell	-5,800	Closed	-$367K	–	2469
2020 Q3	$367K	Sell	5,800 -120,470	-95%	-$8.35M	﹤0.01%	1936
2020 Q2	$9.71M	Sell	126,270 -30,069	-19%	-$2.3M	0.03%	564
2020 Q1	$11.7M	Sell	156,339 -3,056,101	-95%	-$211M	0.04%	435
2019 Q4	$209M	Sell	3,212,440 -1,491,900	-32%	-$97.2M	0.48%	45
2019 Q3	$298M	Sell	4,704,340 -531,300	-10%	-$34.7M	0.73%	22
2019 Q2	$354M	Buy	5,235,640 +1,328,600	+34%	+$87.4M	0.88%	12
2019 Q1	$254M	Buy	3,907,040 +2,802,200	+254%	+$186M	0.64%	21
2018 Q4	$69.1M	Buy	1,104,840 +1,031,502	+1,407%	+$72.1M	0.19%	139
2018 Q3	$5.66M	Sell	73,338 -17,600	-19%	-$1.33M	0.01%	784
2018 Q2	$6.44M	Sell	90,938 -59,499	-40%	-$4.2M	0.02%	745
2018 Q1	$11.3M	Sell	150,437 -598,145	-80%	-$47.5M	0.03%	538
2017 Q4	$53.6M	Sell	748,582 -2,558,687	-77%	-$194M	0.14%	183
2017 Q3	$268M	Sell	3,307,269 -940,869	-22%	-$71.9M	0.76%	13
2017 Q2	$301M	Buy	4,248,138 +226,600	+6%	+$15.1M	0.99%	4
2017 Q1	$273M	Buy	4,021,538 +644,895	+19%	+$45.3M	0.9%	3
2016 Q4	$242M	Buy	3,376,643 +551,847	+20%	+$41M	0.92%	4
2016 Q3	$223M	Buy	2,824,796 +976,097	+53%	+$79.3M	0.95%	9
2016 Q2	$154M	Sell	1,848,699 -232,900	-11%	-$20.7M	0.78%	15
2016 Q1	$191M	Buy	2,081,599 +1,622,761	+354%	+$146M	1.07%	7
2015 Q4	$46.4M	Sell	458,838 -1,107,855	-71%	-$115M	0.28%	99
2015 Q3	$154M	Buy	1,566,693 +371,204	+31%	+$41.2M	0.97%	4
2015 Q2	$140M	Sell	1,195,489 -146,339	-11%	-$16M	1.04%	2
2015 Q1	$132M	Buy	1,341,828 +1,095,010	+444%	+$111M	0.97%	4
2014 Q4	$23.3M	Sell	246,818 -209,300	-46%	-$21.6M	0.18%	135
2014 Q3	$48.6M	Buy	456,118 +447,560	+5,230%	+$43.8M	0.37%	67
2014 Q2	$710K	Buy	+8,558	New	+$666K	0.01%	1410
2014 Q1	–	Sell	-52,328	Closed	-$4.1M	–	2363
2013 Q4	$3.93M	Buy	52,328 +40,800	+354%	+$2.84M	0.04%	453
2013 Q3	$724K	Buy	11,528 +2,900	+34%	+$173K	0.01%	1153
2013 Q2	$442K	Buy	+8,628	New	+$450K	0.01%	1411

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Two Sigma Advisers's GILD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 52,000 shares — an estimated $6.38M sold.

Two Sigma Advisers first reported a position in GILD in Q2 2013 and held it in 48 quarters. The position peaked at $434M in Q1 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Two Sigma Advisers reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 52,000 Gilead Sciences shares in Q1 2026, an estimated $6.38M.
Two Sigma Advisers first reported a position in Gilead Sciences in Q2 2013 and held it in 48 quarters.
Two Sigma Advisers's Gilead Sciences position peaked at $434M in Q1 2023.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.